Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2531279 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2535592 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2526028 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2533637 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2530037 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2532275 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2529354 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| Iodide SCHEMBL2531357 | 1.00 | KDM4E (0.38) | KDM4ENPC1LMNAHTTRAB9A | |
| SCHEMBL11999067 | 0.98 | BCHE (0.39) | — | |
| Iodide SCHEMBL2530880 | 0.98 | KDM4E (0.34) | KDM4ENPC1LMNAHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632914-B2 | Triazolium and imidazolium salts and uses thereof | UNIVERSITY HEALTH NETWORK (CA) | 2014-01-21 | — | — | US | disclosed |
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-20 | — | — | US | disclosed |
| WO-2010025558-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF AS ANTIMALARIALS | UNIVERSITY HAEALTH NETWORK (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257235-A1 | TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF | ARG2, ARG1, CIT | KDM4E 3006/4885NPC1 3713/4885LMNA 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.